Yazar "Yildiz, Yasar" seçeneğine göre listele

Listeleniyor 1 - 7 / 7
  • Küçük Resim Yok
    Öğe
    The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
    (Lippincott Williams & Wilkins, 2022) Ozdemir, Ozlem; Zengel, Baha; Yildiz, Yasar; Uluc, Basak Oyan; Cabuk, Devrim; Ozden, Ercan; Salim, Derya Kivrak
    In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches.
  • Küçük Resim Yok
    Öğe
    Importance of surveillance and risk factor evaluation in patients with multiple curable malignancies
    (Lippincott Williams & Wilkins, 2015) Varol, Umut; Yildiz, Yasar; Varol, Yelda; Alacacioglu, Ahmet; Uslu, Ruchan
  • Küçük Resim Yok
    Öğe
    Importance of surveillance and risk factor evaluation in patients with multiple curable malignancies
    (Lippincott Williams & Wilkins, 2015) Varol, Umut; Yildiz, Yasar; Varol, Yelda; Alacacioglu, Ahmet; Uslu, Ruchan
  • Küçük Resim Yok
    Öğe
    Importance of surveillance and risk factor evaluation in patients with multiple curable malignancies
    (Lippincott Williams & Wilkins, 2015) Varol, Umut; Yildiz, Yasar; Varol, Yelda; Alacacioglu, Ahmet; Uslu, Ruchan
  • Küçük Resim Yok
    Öğe
    Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review
    (Kare Publ, 2021) Ozdemir, Ozlem; Zengel, Baha; Yildiz, Yasar; Saray, Seray; Alacacioglu, Ahmet; Tasli, Funda; Erdi, Zuleyha Can
    Objectives: Neuroendocrine breast carcinoma (NEBC) is a rare subgroup of breast cancer, which makes up 2-5% of all invasive breast cancers. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs. Methods: We retrospectively analyzed clinical, pathological, and radiological characteristics of 36 patients diagnosed with neuroendocrine differentiated breast cancer between 2008 and 2019 compared to that of 925 patients with invasive ductal carcinoma (IDC/NOS) along with a literature review. Results: In this study, 36 patients with neuroendocrine differentiated breast carcinoma and 961 patients with (IDC/NOS), as the comparison group, were identified between 2008 and 2019. In NEBC patients, seven were premenopausal and 29 postmenopausal. Patients whose ultrasound (USG), magnetic resonance, and mammographic (MMG) images available in our hospital, high-density masses were detected in the MMG with irregular (77%), microlobulated (80%) and spiculated margins (63%), unaccompanied by asymmetry and structural distortion. Calcifications were less common than invasive breast cancer, present only in four patients (17%). When NEBC were compared to ductal carcinomas (n=925), NEBC were more often human epidermal growth factor receptor 2 negative (p=0.039), estrogen receptor positive (p=0.05), progesterone receptor positive (0.03), and the NEBC patients were older (p=0.02). Age, grade, metastatic status, lymph node number, and molecular type were identified as prognostic factors that significantly affect survival in both groups (p<0.05). Conclusion: NEBC is a subtype that is both histopathologically and radiologically distinct from other breast cancer subtypes, and neuroendocrine differentiation may be an important predictive marker in the future.
  • Küçük Resim Yok
    Öğe
    Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
    (Sage Publications Ltd, 2018) Yildiz, Ibrahim; Bilici, Ahmet; Karadurmus, Nuri; Ozer, Leyla; Tural, Deniz; Kaplan, Mehmet A.; Akman, Tulay; Bayoglu, Ibrahim, V; Uysal, Mukremin; Yildiz, Yasar; Tanriverdi, Ozgur; Yazici, Ozan; Surmeli, Zeki; Turhal, Nazim Serdar; Bavbek, Sevil; Selcukbiricik, Fatih; Koca, Dogan; Basaran, Mert
    Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.
  • Küçük Resim Yok
    Öğe
    Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
    (Asian Pacific Organization Cancer Prevention, 2014) Bayoglu, Ibrahim Vedat; Varol, Umut; Yildiz, Ibrahim; Muslu, Ugur; Alacacioglu, Ahmet; Kucukzeybek, Yuksel; Akyol, Murat; Demir, Lutfiye; Dirican, Ahmet; Cokmert, Suna; Yildiz, Yasar; Karabulut, Bulent; Uslu, Ruchan; Tarhan, Mustafa Oktay
    Background: The role of second-line therapy in metastatic pancreatic cancer is not clear. In this study, we aimed to explore the second-line efficiency of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer who have received gemcitabine-based first-line therapy. Materials and Methods: We retrospectively evaluated 47 patients with locally advanced or metastatic pancreatic cancer previously treated with gemcitabine-based first-line regimens. Treatment consisted of oxaliplatin 130 mg/m(2) and capecitabine 1000 mg/m2 twice daily with a 3 week interval, until unacceptable toxicity or disease progression. Results: Median number of cycles was 4 (range, 2-10). The overall disease control rate was 38.3%. The median overall survival and progression-free survival from the start of second-line therapy were 23 weeks (95% CI: 16.6-29.5 weeks) and 12 weeks (95% CI: 9.8-14.4 weeks), respectively. The most common grade 3-4 toxicities were nausea, vomiting and hematologic side effects. Conclusions: Our result suggests that the combination of capecitabine and oxaliplatin was tolerated with manageable toxicity and showed encouraging activity as second-line treatment of advanced or metastatic pancreatic cancer patients with ECOG performance status 0-2.